0 items
Your cart is empty.
If you are looking to buy Repatha or order cardiovascular medication online from a verified Canadian supplier with cold-chain expertise, Elivena delivers. This category brings together the leading prescription therapies for LDL cholesterol management and cardiovascular risk reduction — anchored by Repatha (evolocumab), the PCSK9 inhibitor with the strongest outcomes evidence in lipid management — sourced from licensed Canadian pharmacies with full cold-chain compliance.
We work with leading pharmaceutical brands specializing in Cardiovascular Medication medications, selected for their clinical reliability, regulatory compliance, and consistent treatment outcomes.
Effective cardiovascular medication does more than lower a number on a lab report. The clinical benefits of sustained LDL-C reduction translate into fewer life-altering events — heart attacks that do not happen, strokes that do not occur, hospitalisations that are avoided. For high-risk patients, these medications are among the most impactful interventions in all of preventive medicine.
The GLAGOV trial demonstrated that adding evolocumab to statin therapy produced significant regression of coronary artery plaque volume — one of the first direct demonstrations that aggressive LDL-C reduction can physically reverse atherosclerosis rather than merely slow its progression. For patients with established ASCVD, this means Repatha is not just preventing future events — it is actively improving the underlying disease state.
The FOURIER-OLE open-label extension study showed that the cardiovascular benefit of Repatha continues to grow with longer duration of treatment — the longer LDL stays low, the more accumulated protection builds. No new safety signals emerged over five or more years of follow-up. For a patient population that requires lifelong risk management, this long-term safety and sustained benefit profile is essential.
The FOURIER trial’s benefits were consistent across all major subgroups — patients with diabetes, prior stroke, peripheral arterial disease, and multiple vascular territories. Repatha is not a niche therapy for a narrow population. It is a broadly applicable cardiovascular risk reduction tool for any high-risk patient whose LDL-C is not at target on their current regimen.
When you buy Repatha or order cardiovascular medication through Elivena, you access the most evidence-backed options in lipid management and cardiovascular risk reduction.
Repatha (Evolocumab)
The most evidence-backed PCSK9 inhibitor available. Demonstrated 27% reduction in heart attack risk and 21% reduction in stroke risk in the FOURIER outcomes trial of over 27,000 patients. Full cold-chain supply managed by Elivena. See Repatha 140 mg.
Ozempic (Semaglutide)
GLP-1 receptor agonist with demonstrated cardiovascular outcomes benefits in the SUSTAIN-6 and SELECT trials. Relevant for patients managing both Type 2 diabetes and cardiovascular risk. See Ozempic.
Mounjaro (Tirzepatide)
Dual GIP/GLP-1 receptor agonist with strong cardiometabolic data — significant reductions in LDL-C, body weight, and cardiovascular risk markers across multiple studies. See Mounjaro.
Other cardiovascular and metabolic products available at Elivena include:
Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9 — the protein responsible for degrading LDL receptors on the liver surface. By blocking PCSK9, Repatha allows significantly more LDL receptors to remain active, enabling the liver to clear far more LDL cholesterol from the bloodstream. The result is an LDL-C reduction of 55 to 75% on top of statin therapy — a level of cholesterol lowering that no oral medication has been able to match.
Repatha is indicated for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction beyond diet and maximally tolerated statin therapy. It is available at Elivena as Repatha 140 mg/mL in a single-use pre-filled autoinjector.
The liver clears LDL cholesterol from the blood using receptors on the hepatocyte surface. Each receptor captures an LDL particle, internalises it, and then recycles back to the surface to capture another. PCSK9 is a protein the liver produces that interferes with this recycling — it binds to LDL receptors after they internalise their LDL particle and targets them for destruction rather than allowing them to return to the surface.
Evolocumab — Repatha’s active ingredient — is a monoclonal antibody that binds to PCSK9 with high affinity and prevents it from interacting with LDL receptors. With PCSK9 neutralised, LDL receptors recycle efficiently to the liver surface, dramatically increasing the liver’s LDL-clearing capacity. Because this mechanism is entirely independent of how statins work, Repatha adds meaningful LDL reduction on top of any statin regimen — including maximum doses.
LDL cholesterol is the primary modifiable lipid risk factor for cardiovascular disease. When LDL levels are persistently elevated, cholesterol gradually deposits on arterial walls, forming plaques that narrow and harden the arteries — a process called atherosclerosis. These plaques can rupture without warning, triggering blood clots that cause heart attacks and strokes.
The relationship between LDL-C reduction and cardiovascular risk reduction is linear and well established. Every 1 mmol/L reduction in LDL-C is associated with approximately a 20–25% reduction in major cardiovascular events. Current guidelines recommend LDL-C targets below 1.4 mmol/L for very high-risk patients — levels that the majority of patients on statin therapy alone cannot reach. This is precisely the gap that Repatha closes.
What is Repatha used for?
How much does Repatha lower LDL cholesterol?
Who qualifies for PCSK9 inhibitor therapy?
Does Repatha need to be refrigerated?
Is a prescription required to order Repatha from Elivena?
